Premature Ejaculation - Pipeline Review, H1 2015

Description: Premature Ejaculation - Pipeline Review, H1 2015

Summary

This, ‘Premature Ejaculation - Pipeline Review, H1 2015’, provides an overview of the Premature Ejaculation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premature Ejaculation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Ejaculation and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Premature Ejaculation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Premature Ejaculation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Premature Ejaculation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Premature Ejaculation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Premature Ejaculation pipeline depth and focus of indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

<table>
<thead>
<tr>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of Tables</td>
</tr>
<tr>
<td>List of Figures</td>
</tr>
<tr>
<td>Introduction</td>
</tr>
<tr>
<td>REPORT COVERAGE</td>
</tr>
<tr>
<td>Premature Ejaculation Overview</td>
</tr>
<tr>
<td>Therapeutics Development</td>
</tr>
<tr>
<td>Pipeline Products for Premature Ejaculation - Overview</td>
</tr>
<tr>
<td>Pipeline Products for Premature Ejaculation - Comparative Analysis</td>
</tr>
<tr>
<td>Premature Ejaculation - Therapeutics under Development by Companies</td>
</tr>
<tr>
<td>Premature Ejaculation - Pipeline Products Glance</td>
</tr>
<tr>
<td>Late Stage Products</td>
</tr>
<tr>
<td>Clinical Stage Products</td>
</tr>
<tr>
<td>Early Stage Products</td>
</tr>
<tr>
<td>Premature Ejaculation - Products under Development by Companies</td>
</tr>
<tr>
<td>Premature Ejaculation - Companies Involved in Therapeutics Development</td>
</tr>
<tr>
<td>Actavis plc</td>
</tr>
<tr>
<td>Dong-A Socio Group</td>
</tr>
<tr>
<td>NeuroHealing Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>Plethora Solutions Holdings plc</td>
</tr>
<tr>
<td>SK Chemicals Co., Ltd.</td>
</tr>
<tr>
<td>Yungjin Pharm Ind. Co., Ltd.</td>
</tr>
<tr>
<td>Premature Ejaculation - Therapeutics Assessment</td>
</tr>
<tr>
<td>Assessment by Monotherapy Products</td>
</tr>
<tr>
<td>Assessment by Combination Products</td>
</tr>
<tr>
<td>Assessment by Target</td>
</tr>
<tr>
<td>Assessment by Mechanism of Action</td>
</tr>
<tr>
<td>Assessment by Route of Administration</td>
</tr>
<tr>
<td>Assessment by Molecule Type</td>
</tr>
<tr>
<td>Drug Profiles</td>
</tr>
<tr>
<td>(lidocaine + prilocaine) - Drug Profile</td>
</tr>
<tr>
<td>Product Description</td>
</tr>
<tr>
<td>Mechanism of Action</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
</tr>
<tr>
<td>DA-8031 - Drug Profile</td>
</tr>
<tr>
<td>Product Description</td>
</tr>
<tr>
<td>Mechanism of Action</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
</tr>
<tr>
<td>IX-01 - Drug Profile</td>
</tr>
<tr>
<td>Product Description</td>
</tr>
<tr>
<td>Mechanism of Action</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
</tr>
<tr>
<td>modafinil - Drug Profile</td>
</tr>
<tr>
<td>Product Description</td>
</tr>
<tr>
<td>Mechanism of Action</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
</tr>
<tr>
<td>NCE-405 - Drug Profile</td>
</tr>
<tr>
<td>Product Description</td>
</tr>
<tr>
<td>Mechanism of Action</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
</tr>
<tr>
<td>onabotulinumtoxin A - Drug Profile</td>
</tr>
<tr>
<td>Product Description</td>
</tr>
<tr>
<td>Mechanism of Action</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
</tr>
<tr>
<td>tramadol hydrochloride - Drug Profile</td>
</tr>
<tr>
<td>Product Description</td>
</tr>
</tbody>
</table>
Mechanism of Action
R&D Progress
YPE-1706 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Premature Ejaculation - Recent Pipeline Updates
Premature Ejaculation - Dormant Projects
Premature Ejaculation - Discontinued Products
Premature Ejaculation - Product Development Milestones
Featured News & Press Releases
Jan 08, 2015: Vyrix Pharmaceuticals to Present at Biotech Showcase 2015
Nov 11, 2014: Plethora Solutions Provides Company Update
Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU
Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment
Mar 11, 2014: Plethora Solutions Provides Company update
Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation
Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation
Jul 01, 2013: AGM Statement & PSD502 Regulatory Update
Jun 03, 2013: Ampio Pharma Provides Update On Sexual Dysfunction Portfolio
Mar 11, 2013: Ampio Receives FDA Acceptance Of Patient Outcome For Premature Ejaculation Questionnaire
Paving Way For US Pivotal Trial On Zertane
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Premature Ejaculation, H1 2015
Number of Products under Development for Premature Ejaculation - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Premature Ejaculation - Pipeline by Actavis plc, H1 2015
Premature Ejaculation - Pipeline by Dong-A Socio Group, H1 2015
Premature Ejaculation - Pipeline by NeuroHealing Pharmaceuticals Inc., H1 2015
Premature Ejaculation - Pipeline by Plethora Solutions Holdings plc, H1 2015
Premature Ejaculation - Pipeline by SK Chemicals Co., Ltd., H1 2015
Premature Ejaculation - Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Premature Ejaculation Therapeutics - Recent Pipeline Updates, H1 2015
Premature Ejaculation - Dormant Projects, H1 2015
Premature Ejaculation - Dormant Projects (Contd..1), H1 2015
Premature Ejaculation - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Premature Ejaculation, H1 2015
Number of Products under Development for Premature Ejaculation - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3243294/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: Premature Ejaculation - Pipeline Review, H1 2015
- Web Address: http://www.researchandmarkets.com/reports/3243294/
- Office Code: SCD2SINL

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

- Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
- First Name: ___________________________ Last Name: ___________________________

- Email Address: * ___________________________
- Job Title: ___________________________
- Organisation: ___________________________
- Address: ___________________________
- City: ___________________________
- Postal / Zip Code: ___________________________
- Country: ___________________________
- Phone Number: ___________________________
- Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World